Skip to main content
. 2022 Oct 26;29(2):401–409. doi: 10.1158/1078-0432.CCR-22-2509

Table 3.

Objective response rate (CR + PR) and clinical benefit rate (CR + PR + ≥6 months of SD) between matched and unmatched patients with URS on Phase 1 clinical trials.

Matched treatment Unmatched treatment P
Total patients 33 73
Objective response rate (n) 24% (8) 8.2% (6) 0.024
Clinical benefit (n) 36.4% (12) 26% (19) 0.279